Many early cell and gene therapies (CGTs) achieved strong initial uptake due to their groundbreaking nature. As the CGT market has entered the next phase of growth, however, strong science alone is no longer sufficient to drive success. Based on current market dynamics, Blue Matter has identified 10 commercialization success factors distinguishing successful CGT therapies from those that struggle. This paper provides a clear and concise overview of each.
